Degarelix (Firmagon) for prostate cancer: now approved by FDA

Related to EMEA’s positive opinion on degarelix (Firmagon) for prostate cancer, FDA issues this press release dated Dec. 29, 2008: FDA Approves Drug for Patients with Advanced Prostate Cancer The U.S. Food and Drug Administration recently approved the injectable drug degarelix, the first new drug in several years for prostate cancer.  

Are you a visual learner interested in learning psychopharmacology? Click here to get our videos